Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): Results of the Japanese AMD Trial (JAT) extension

Masahito Ohji, Yasuo Tano, Neil M. Bressler, Tatsuro Ishibashi, Fumio Shiraga, Kanji Takahashi, Annemarie Weisberger, Mitsuko Yuzawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: To evaluate the longer term safety of verteporfin therapy in Japanese patients with subfoveal classic choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Methods: Patients completing 12 months of the Japanese AMD Trial (JAT) were eligible to enter the extension phase if the investigator judged they would potentially benefit from further verteporfin therapy. Patients had follow-up visits every 3 months, receiving verteporfin therapy in the study eye if leakage from CNV was observed on fluorescein angiography. Mean change from baseline in best-corrected visual acuity was a safety variable in the extension. Results: Of the 51 patients entering the study extension, 46 (90%) completed 24 months. Adverse events were similar to those in the first 12 months of JAT; no cumulative toxic effect of verteporfin therapy was identified. Mean visual acuity letter score in the study eye increased from 50.8 (20/100+1 at baseline to 54.0 (20/80 -1) at month 24. At month 24, six patients (13%) had lost 15 or more letters of visual acuity, of whom four (9%) had lost 30 or more letters. Conclusion: Verteporfin therapy was shown to be safe and effective through 24 months in Japanese patients with subfoveal CNV due to AMD, supporting its long-term use in these patients.

Original languageEnglish
Pages (from-to)99-107
Number of pages9
JournalJapanese Journal of Ophthalmology
Volume52
Issue number2
DOIs
Publication statusPublished - Apr 1 2008

Fingerprint

Choroidal Neovascularization
Photochemotherapy
Macular Degeneration
Visual Acuity
Therapeutics
Safety
Fluorescein Angiography
Poisons
verteporfin
Research Personnel

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) : Results of the Japanese AMD Trial (JAT) extension. / Ohji, Masahito; Tano, Yasuo; Bressler, Neil M.; Ishibashi, Tatsuro; Shiraga, Fumio; Takahashi, Kanji; Weisberger, Annemarie; Yuzawa, Mitsuko.

In: Japanese Journal of Ophthalmology, Vol. 52, No. 2, 01.04.2008, p. 99-107.

Research output: Contribution to journalArticle

@article{25a9db47339d4b66b4f60d986714e531,
title = "Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): Results of the Japanese AMD Trial (JAT) extension",
abstract = "Purpose: To evaluate the longer term safety of verteporfin therapy in Japanese patients with subfoveal classic choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Methods: Patients completing 12 months of the Japanese AMD Trial (JAT) were eligible to enter the extension phase if the investigator judged they would potentially benefit from further verteporfin therapy. Patients had follow-up visits every 3 months, receiving verteporfin therapy in the study eye if leakage from CNV was observed on fluorescein angiography. Mean change from baseline in best-corrected visual acuity was a safety variable in the extension. Results: Of the 51 patients entering the study extension, 46 (90{\%}) completed 24 months. Adverse events were similar to those in the first 12 months of JAT; no cumulative toxic effect of verteporfin therapy was identified. Mean visual acuity letter score in the study eye increased from 50.8 (20/100+1 at baseline to 54.0 (20/80 -1) at month 24. At month 24, six patients (13{\%}) had lost 15 or more letters of visual acuity, of whom four (9{\%}) had lost 30 or more letters. Conclusion: Verteporfin therapy was shown to be safe and effective through 24 months in Japanese patients with subfoveal CNV due to AMD, supporting its long-term use in these patients.",
author = "Masahito Ohji and Yasuo Tano and Bressler, {Neil M.} and Tatsuro Ishibashi and Fumio Shiraga and Kanji Takahashi and Annemarie Weisberger and Mitsuko Yuzawa",
year = "2008",
month = "4",
day = "1",
doi = "10.1007/s10384-008-0512-3",
language = "English",
volume = "52",
pages = "99--107",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD)

T2 - Results of the Japanese AMD Trial (JAT) extension

AU - Ohji, Masahito

AU - Tano, Yasuo

AU - Bressler, Neil M.

AU - Ishibashi, Tatsuro

AU - Shiraga, Fumio

AU - Takahashi, Kanji

AU - Weisberger, Annemarie

AU - Yuzawa, Mitsuko

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Purpose: To evaluate the longer term safety of verteporfin therapy in Japanese patients with subfoveal classic choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Methods: Patients completing 12 months of the Japanese AMD Trial (JAT) were eligible to enter the extension phase if the investigator judged they would potentially benefit from further verteporfin therapy. Patients had follow-up visits every 3 months, receiving verteporfin therapy in the study eye if leakage from CNV was observed on fluorescein angiography. Mean change from baseline in best-corrected visual acuity was a safety variable in the extension. Results: Of the 51 patients entering the study extension, 46 (90%) completed 24 months. Adverse events were similar to those in the first 12 months of JAT; no cumulative toxic effect of verteporfin therapy was identified. Mean visual acuity letter score in the study eye increased from 50.8 (20/100+1 at baseline to 54.0 (20/80 -1) at month 24. At month 24, six patients (13%) had lost 15 or more letters of visual acuity, of whom four (9%) had lost 30 or more letters. Conclusion: Verteporfin therapy was shown to be safe and effective through 24 months in Japanese patients with subfoveal CNV due to AMD, supporting its long-term use in these patients.

AB - Purpose: To evaluate the longer term safety of verteporfin therapy in Japanese patients with subfoveal classic choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Methods: Patients completing 12 months of the Japanese AMD Trial (JAT) were eligible to enter the extension phase if the investigator judged they would potentially benefit from further verteporfin therapy. Patients had follow-up visits every 3 months, receiving verteporfin therapy in the study eye if leakage from CNV was observed on fluorescein angiography. Mean change from baseline in best-corrected visual acuity was a safety variable in the extension. Results: Of the 51 patients entering the study extension, 46 (90%) completed 24 months. Adverse events were similar to those in the first 12 months of JAT; no cumulative toxic effect of verteporfin therapy was identified. Mean visual acuity letter score in the study eye increased from 50.8 (20/100+1 at baseline to 54.0 (20/80 -1) at month 24. At month 24, six patients (13%) had lost 15 or more letters of visual acuity, of whom four (9%) had lost 30 or more letters. Conclusion: Verteporfin therapy was shown to be safe and effective through 24 months in Japanese patients with subfoveal CNV due to AMD, supporting its long-term use in these patients.

UR - http://www.scopus.com/inward/record.url?scp=43049087047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049087047&partnerID=8YFLogxK

U2 - 10.1007/s10384-008-0512-3

DO - 10.1007/s10384-008-0512-3

M3 - Article

C2 - 18626732

AN - SCOPUS:43049087047

VL - 52

SP - 99

EP - 107

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 2

ER -